Scenesse is an orphan drug. That means the safety and efficacy standards for approval are much lower than normal. If it widely used (eg strokes) it must meet the far higher standards required for normal approval.
The fact that alpha-MSH drugs have been totally ignored for 40 years by Big Pharma suggest they aren't very good.
HC ínvestors are almost invariably far too greedy and totally unrealistic about the prospects of their holdings.
Ann: Media release - First stroke patient with afamelanotide, page-19
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.68 |
Change
-0.240(1.61%) |
Mkt cap ! $735.1M | |||
| Open | High | Low | Value | Volume |
| $14.75 | $14.92 | $14.65 | $503.5K | 34.18K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 448 | $14.68 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.74 | 149 | 1 |
View Market Depth
| Last trade - 16.10pm 02/08/2024 (20 minute delay) ? |
| CUV (ASX) Chart |